Results 11 to 20 of about 3,831 (231)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections [PDF]

Future Microbiology, 2019
Aim: Meropenem-vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Ryan K. Shields, Erin K McCreary, Rachel V Marini, Ellen G Kline, Chelsea E Jones, Binghua Hao, Cornelius J. Clancy, M. Hong Nguyen   +7 more
core   +8 more sources

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica [PDF]

MicrobiologyOpen
Nocardiosis is an infectious disease caused by several Nocardia species, among which Nocardia cyriacigeorgica is one of the most frequently isolated species in the clinic.
Julie Couston, Athénaïs Le Marchand, Elisabeth Hodille, Charlotte Genestet, Brune Joannard, Jérôme Feuillard, Yvonne Benito, Oana Dumitrescu, Mickaël Blaise   +8 more
doaj   +3 more sources

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Microbiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero   +6 more
doaj   +3 more sources

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018 [PDF]

Antibiotics, 2021
Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing K.
Paolo Gaibani, Donatella Lombardo, Linda Bussini, Federica Bovo, Beatrice Munari, Maddalena Giannella, Michele Bartoletti, Pierluigi Viale, Tiziana Lazzarotto, Simone Ambretti   +9 more
doaj   +3 more sources

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.
Christopher M Rubino, Michael N Dudley, David C Griffith   +2 more
exaly   +3 more sources

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance [PDF]

Antibiotics, 2023
Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives.
Anna Duda-Madej, Szymon Viscardi, Ewa Topola   +2 more
doaj   +2 more sources

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Olga Lomovskaya, Dongxu Sun, Ruslan Tsivkovski   +2 more
exaly   +3 more sources

Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Debora, Rubio-Aparicio, Jeff, Loutit, Michael, Dudley, Olga, Lomovskaya   +3 more
openaire   +3 more sources

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Chi-Chung Chen, Hung-Jen Tang   +2 more
openaire   +4 more sources

Profiling interactions of vaborbactam with metallo-β-lactamases [PDF]

Bioorganic & Medicinal Chemistry Letters, 2019
β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and the metallo β-lactamases that utilise a zinc-bound water nucleophile.
Langley, G, Cain, R, Tyrrell, J, Hinchliffe, P, Calvopiña, K, Tooke, C, Widlake, E, Dowson, C, Spencer, J, Walsh, T, Schofield, C, Brem, J   +11 more
core   +12 more sources